Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: A Probe Study of Acamprosate: Genes Associated With Response
Brief Summary: In 2004, acamprosate was approved in the U.S. for abstinence maintenance, by decreasing craving, in alcoholic patients who have undergone detoxification. while a new anti-craving drug was encouraging, only 36.1% of the subjects treated with acamprosate remained abstinent for 6 months. Having the ability to identify treatment responsive individuals would have a major impact on the use of acamprosate.